Loading clinical trials...
Loading clinical trials...
A Randomized, Open-Label, Controlled, International Multi-Center Phase III Clinical Study of Camrelizumab Combined With Rivoceranib (Apatinib) Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Hepatocellular Carcinoma (HCC) Who Have Been Treated With Immune Checkpoint Inhibitors (ICIs)
Conditions
Interventions
camrelizumab；Rivoceranib
Rivoceranib
+2 more
Locations
1
China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Start Date
September 26, 2021
Primary Completion Date
December 29, 2021
Completion Date
December 29, 2021
Last Updated
September 1, 2022
NCT07039201
NCT06737913
NCT01101906
NCT04212221
NCT04605796
Lead Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions